All articles by Prasanth Katam

Prasanth Katam

May’s top stories: Thermo Fisher Scientific buys Patheon for $7.2bn, AstraZeneca to sell rights for Seloken

Thermo Fisher Scientific agreed to acquire Dutch contract development and manufacturing organisation (CDMO) Patheon for $7.2bn. AstraZeneca entered an agreement to provide the commercial rights for Seloken / Seloken ZOK and associated Logimax fixed-dose combination treatments in Europe to Recordati. wraps up the key headlines from May.

September’s top stories: Mylan’s bid to buy Perrigo, treatment for dengue

Endo acquires Par Pharmaceutical for $8bn, London’s Moorfields Eye Hospital treats first patient with stem cell therapy for wet AMD, Pfizer launches Sayana Press self-injectable contraceptive in UK. wraps up the key headlines from September 2015.

July’s top stories: Teva buys Allergan, Garlic treats antimicrobial resistant UTIs

15-year-old Briton develops new test for Alzheimer’s disease, UK researchers repair damaged liver using stem cells and Celgene plans to buy Receptos for $7.2bn. wraps up the key headlines from July.

June’s top stories: First head transplant, Merck’s $17bn deal for Sigma-Aldrich

Plans were announced for the world’s first head transplant, a £10bn ‘megafund’ was detailed in London for pharma development, Merck received European approval for $17bn acquisition of Sigma-Aldrich, and a study showed that cancer drugs can delay the ageing process in fruit flies. wraps-up the key headlines from June 2015.

May’s top stories: Mylan’s offer to Perrigo, new HIV Cure Centre

AbbVie acquired biopharmaceutical firm Pharmacyclics for $21bn, GSK and UNC-Chapel Hill announced the creation of its HIV Cure Centre, and AstraZeneca unveiled plans to develop a new $285m biologics manufacturing facility in Sweden. wraps-up the key headlines from May 2015.

April’s top stories: Teva’s offer to Mylan, Takeda settles with US

Mylan buys Perrigo and Teva made bid to acquire Mylan, Takeda to pay $2.4bn to settle Actos drug claims in US, and researchers developed a new biochip to enhance drug discoveries. wraps-up the key headlines from April 2015.

March’s top stories: Salix sold to Valeant, global drug development partnerships

Salix accepted Valeant’s $15.8bn offer, AstraZeneca and HSCI partnered to develop new medicines for diabetes; while India introduced new Rotavirus vaccine. wraps-up the key headlines from March 2015.

February’s top stories: Three-person IVF in UK, Pfizer-Hospira purchase deal

UK MPs voted in favour of three-person IVF technique; Merck and MPP partnered to supply paediatric HIV drug in developing nations; and an independent review called for more funding to tackle drug-resistant infections. wraps-up the key headlines from February 2015.

January’s top stories: Pfizer’s investors deal, Eli Lilly buys Novartis business

Pfizer agreed for a $400m settlement with investors, Eli Lilly bought Novartis Animal Health, and MSG pleads for a cut in pneumococcal vaccine price. wraps up the key headlines from January 2015.

2014: The year’s biggest Pharmaceutical Technology stories

Ireland-based pharmaceutical company Actavis signed an agreement to acquire US-based Botox-maker Allergan for $66bn or $219 per share.